-

Adagio Medical to Participate at the TD Cowen's 45th Annual Health Care Conference

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that management will be attending TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at the Marriott Copley Place in Boston, MA.

About Adagio Medical

Adagio Medical is an early commercial stage medical device company located in Laguna Hills, California focusing on developing proprietary Ultra-Low Temperature Cryoablation technology that creates contiguous, transmural lesions to treat cardiac arrhythmias, with an emphasis on ventricular tachycardia.

Contacts

Media:
Ilya Grigorov
Vice President, Global Marketing and Product Management of Adagio Medical, Inc.
igrigorov@adagiomedical.com

Investor:
IR@adagiomedical.com

Industry:

Adagio Medical Holdings, Inc.

NASDAQ:ADGM
Release Versions
English

Contacts

Media:
Ilya Grigorov
Vice President, Global Marketing and Product Management of Adagio Medical, Inc.
igrigorov@adagiomedical.com

Investor:
IR@adagiomedical.com

More News From Adagio Medical Holdings, Inc.

Adagio Medical to Participate in the TD Cowen 46th Annual Healthcare Conference

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at 2:30 PM ET in Boston, MA. Presentation Information A live webcast and replay of the session will be accessible at https://event.summitcast.com or on the Company...

New Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broad Range of Patients with Ventricular Tachycardia

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of results from the U.S. Early Feasibility Study (“EFS”) evaluating ultralow temperature cardiac ablation (“ULTC”) for the treatment of scar-related ventricular tachycardia (“VT”). The study was published in Circulation: Arrythmia and Electrophysiology. The p...

Adagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 10, 2026 in Snowbird, UT. About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing...
Back to Newsroom